Liminatus Pharma Inc Cl A (LIMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | |
| Operating Expenses | 543 | 909 | 0 |
| Operating Income | -543 | -909 | 0 |
| Interest Expense | 93 | 77 | 0 |
| Other Income | 34 | 25 | 0 |
| Pre-tax Income | -601 | -961 | 0 |
| Net Income Continuous | -601 | -961 | 0 |
| Net Income | $-601 | $-961 | $0 |
| EPS Basic Total Ops | -0.03 | -0.05 | -2.47 |
| EPS Basic Continuous Ops | -0.03 | -0.05 | 2.47 |
| EPS Diluted Total Ops | -0.03 | -0.05 | -2.47 |
| EPS Diluted Continuous Ops | -0.03 | -0.05 | 2.47 |
| EBITDA(a) | $-543 | $-909 | $0 |